June 2026 Research Update

This month, research most clearly added to the idea that Bardet-Biedl syndrome (BBS) can look very different from person to person, and that genetic results can be the starting point for recognizing BBS when the first obvious problem is vision loss. In a group of families originally thought to have non-syndromic inherited retinal disease, many people also had BBS-related findings once researchers looked for them in a structured way. This supports the real-world experience that BBS may be missed when only one body system is evaluated. [1]

In the Jordanian families studied, obesity and extra body findings like polydactyly, kidney changes, and genitourinary differences were common once the group was re-examined with BBS in mind. A genotype-first approach (using genetic findings to guide a targeted review of symptoms) classified 18 of 19 people as BBS, compared with 11 of 19 using the older Beales symptom-first criteria. For patients, this highlights why someone can be living with BBS even if they were first diagnosed with a retina-only condition. [1]

A separate family report adds to the growing list of known BBS-causing gene changes by describing two siblings with BBS7 variants, including one novel variant that computer and structural analyses supported as likely disease-causing. While this does not prove how the variant changes cell function, it strengthens the link between that specific gene change and the typical BBS pattern across the body, including eye and kidney involvement. Over time, reports like this help genetic testing labs interpret rare results more confidently. [2]

For patients and caregivers, these studies add clarity about diagnosis: BBS may be recognized only after genetic testing prompts a careful look for features beyond the eyes. This may matter now for understanding why symptoms can seem unrelated (for example, vision changes plus weight or kidney issues) and why different diagnostic checklists may not agree. What remains uncertain is how best to standardize gene-first approaches across healthcare systems, and how often newly reported variants (like the BBS7 change described here) will be confirmed by additional families or lab testing.

This month included a small long-term look at how kidney and blood pressure issues can unfold in children with BBS. The main picture was that kidney development differences can be present before or soon after birth, but kidney function did not rapidly decline during childhood in this small group. It also showed that high blood pressure can appear in some children and can be brought under control. [3]

Across four children followed from birth to 10 years, ultrasound findings included kidney injury and bilateral kidney dysplasia, and lab tests of kidney function were generally similar over time rather than steadily worsening. Two children had hypertension that was reported as controlled using ACE inhibitors. Because this was only four children, it cannot describe what will happen for everyone, but it helps illustrate how kidney and blood pressure changes may show up early and then remain stable for years in some patients. [3]

For families, this evidence mainly adds understanding rather than changing care: it offers a concrete example that kidney differences in BBS can start very early, and that kidney function may stay stable through childhood in some people. It also reinforces that blood pressure is part of the BBS health picture, since it was present in 2 children in this series and was managed medically. What remains uncertain is how common this stable pattern is across the wider BBS community, since the report followed only a small number of children.

Several June studies were about building better tools to understand BBS and keep track of its many possible effects, rather than testing treatments. Together, they show progress on three fronts: clearer lab explanations for how certain gene changes affect cilia, new patient-derived cells that can be used for experiments, and a structured plan for organizing monitoring needs across body systems. This kind of work can be slow to translate, but it is how later, more practical studies are made possible. [4] [5] [6]

In a cellular study of BBS1, different disease-associated variants did not all behave the same way. One variant disrupted early steps of building the BBSome (a group of proteins needed for normal cilia function), another impaired later maturation and movement to the cilium, and a third left assembly mostly intact but weakened interactions needed for moving certain receptors out of cilia. For patients, the key meaning is that different gene changes may cause BBS by different internal routes, which can matter for future research that tries to match therapies to specific molecular problems. [4]

A separate laboratory report created an induced pluripotent stem cell (iPSC) line from a person with a BBS5 pathogenic variant and showed that the cells were genetically stable and could develop into different cell types. This provides a renewable source of patient-like cells for studying cilia problems and testing ideas in the lab, but it does not report patient outcomes. [5]

One framework paper described building a clinical decision support structure for monitoring BBS using published evidence and expert input. It cataloged 108 possible clinical manifestations across body systems and organized follow-up into records, schedules, questionnaires, and test trackers. The result is an organizational tool rather than a clinical trial, so it shows the breadth of what can be tracked, not whether this approach improves health outcomes. [6]

For patients and caregivers, these studies mainly matter as early groundwork: they improve the research toolkit for understanding why BBS happens and how its effects might differ by gene variant, and they propose a structured way to keep track of BBS manifestations over time. They do not provide new evidence that a specific monitoring plan changes outcomes, and they do not test any new treatment. What they help clarify is that BBS biology is not one-size-fits-all at the cellular level, and that tracking BBS across many body systems is complex enough that dedicated tools are being built.

This month also included case reports that do not define what most people with BBS will experience, but they do widen awareness of what can happen in complex situations. The shared pattern was severe complications occurring alongside significant medical complexity, with detailed descriptions meant to help future recognition and reporting. Because these are single-patient (or very small) reports, they cannot show how common these problems are. [7] [8]

One report described a child with BBS2 variants who developed Coats-like exudative vasculopathy, a serious problem where abnormal retinal blood vessels leak and can lead to retinal detachment and glaucoma. Despite multiple eye procedures including laser treatment, surgery, and anti-VEGF injections, vision remained limited to light perception or hand motion, while eye pressure was controlled with medications. For families, this case highlights that some retinal complications in BBS may involve blood vessel changes, not only the more typical retinal dystrophy. [7]

Another case report described an adolescent with BBS and end-stage kidney disease who developed acute generalized exanthematous pustulosis (AGEP), a sudden widespread pustular rash that can be triggered by medications, during intensive care for presumed sepsis. The diagnosis was supported by a EuroSCAR score of 9, and the rash improved after stopping suspected drugs and providing supportive skin care, but the patient later died from refractory septic shock. The report underscores the importance of documenting and reporting severe drug reactions when many medications are used in critical illness, even though it cannot show risk levels for others with BBS. [8]

For patients, these reports are mainly about awareness and documentation rather than prediction. They show that, in some individuals with BBS, eye disease can include aggressive blood vessel problems and glaucoma, and that severe medication-related rashes can occur during intensive care when multiple drugs are used. What remains uncertain is how often these complications happen in BBS overall, because case reports cannot estimate frequency or prove that BBS itself caused the complication.